Core Viewpoint - *ST Zhengping has experienced significant stock price fluctuations, with a cumulative increase of 221.93% from September 1 to November 18, 2025, leading to trading suspensions and heightened risks for investors [2] Group 1: Stock Performance and Trading Status - The stock of *ST Zhengping has been suspended three times for trading reviews due to rapid price increases [2] - The company announced that its stock will resume trading on December 3, 2025, after completing the necessary reviews [2] Group 2: Financial Reporting and Audit Issues - The 2024 annual report of *ST Zhengping received an audit report with a disclaimer of opinion due to limited audit scope, resulting in a delisting risk warning for the stock [4] - The company faces significant uncertainties regarding its ability to continue as a going concern, as indicated by a negative opinion on internal controls and the presence of illegal guarantees [4] - If the issues highlighted in the non-standard opinions are not resolved by the end of the 2025 fiscal year, the stock may be delisted [4] Group 3: Financial Performance - In 2024, *ST Zhengping reported revenues of 1.362 billion yuan and a net loss attributable to shareholders of 484 million yuan, with a net loss of 475 million yuan after excluding non-recurring items [5] - For the first three quarters of 2025, the company achieved revenues of 652 million yuan and a net loss of 99 million yuan, with a net loss of 190 million yuan after excluding non-recurring items [5] Group 4: Operational Challenges - The company is facing challenges in mineral resource extraction capabilities, with its subsidiary obtaining a mining license but lacking sufficient funds, personnel, and equipment for further development [4] - As of September 30, 2025, *ST Zhengping had cash reserves of 72.3767 million yuan, with 30.2848 million yuan restricted due to various legal and operational issues, resulting in a high debt ratio of 92.49% [4]

Core Viewpoint - *ST Zhengping has experienced significant stock price fluctuations, with a cumulative increase of 221.93% from September 1 to November 18, 2025, leading to trading risks and subsequent stock suspension for investigation [1][5]. Group 1: Stock Performance and Trading Risks - The stock of *ST Zhengping has seen 26 consecutive trading days of gains since September, with three suspensions for investigation during this period [1][5]. - The company announced that its stock will resume trading on December 3, 2025, after completing the investigation into trading activities [1][5]. - The rapid increase in stock price has created a significant divergence from the Shanghai Composite Index and the construction industry, indicating heightened trading risks [1][5]. Group 2: Financial Performance and Audit Issues - In 2024, *ST Zhengping reported revenue of 1.362 billion yuan and a net loss attributable to shareholders of 484 million yuan, with a non-recurring net loss of 475 million yuan [4][8]. - For the first three quarters of 2025, the company achieved revenue of 652 million yuan and a net loss of 99 million yuan, with a non-recurring net loss of 190 million yuan [4][8]. - The 2024 annual report received an audit opinion that could not express an opinion due to limited audit scope, leading to a delisting risk warning for the stock [3][7]. Group 3: Operational Challenges and Future Uncertainties - The company faces significant uncertainties regarding its ability to develop mineral resources, as it lacks sufficient funds, personnel, and equipment for future mining operations [3][8]. - As of September 30, 2025, *ST Zhengping reported cash holdings of 72.3767 million yuan, with 30.2848 million yuan restricted due to various legal and operational issues, resulting in a high debt ratio of 92.49% [3][8]. - The company has received a mining license for its subsidiary but requires substantial investment for future development, which is currently uncertain due to multiple external factors [3][8].

Core Viewpoint - *ST Suwu has been delisted due to long-term financial fraud and information disclosure violations, with significant implications for its future operations and market presence [2][6]. Financial Misconduct - Since 2018, *ST Suwu has concealed its actual controlling shareholder and inflated its revenue by over 1.77 billion yuan through related party transactions [2][6]. - Approximately 1.69 billion yuan of funds have been non-operationally occupied by related parties, nearly depleting the company's core assets [2][6]. - The company has been fined 10 million yuan, and its actual controller has been fined 15 million yuan and banned from the securities market for 10 years [6]. Business Performance - The company's revenue has significantly declined, with a year-on-year drop of 38.85% in the first three quarters of 2025, resulting in a net loss of 87.468 million yuan [2][8]. - The traditional pharmaceutical sector has also suffered, with a 55.79% decline in revenue during the same period [8]. Legal and Regulatory Issues - In February 2023, *ST Suwu received a notice from the China Securities Regulatory Commission (CSRC) regarding suspected violations of information disclosure laws [5]. - The company faced a series of regulatory actions, including warnings and administrative penalties, culminating in its delisting [5][6]. Product and Market Challenges - The "Tongyan Needle" (AestheFill) has become a critical growth point for *ST Suwu, contributing 35.55% of its revenue in Q1 2025 [7][8]. - A dispute over the agency rights for AestheFill has emerged, with the company facing a potential loss of this key product due to a contract termination by a partner [7][8]. Future Outlook - With the delisting, *ST Suwu faces severe challenges in liquidity and creditworthiness, as it loses access to capital markets [9][10]. - The company must find new revenue sources quickly to survive, as its current financial situation is precarious, with only about 49.19 million yuan in cash remaining [9][10].

ST立方最新披露，公司被查明存在年报虚假记载，2021年至2023年累计虚增营收超6亿元，安徽证 监局对公司及10名相关责任人合计罚款4000万元，多人被采取10年市场禁入措施。 记者关注到，在此番被查明财务造假之前，ST立方去年至今两度更正会计差错，2024年年报被出 具"非标"意见，今年4月底被实施ST。 2025.11. 30 本文字数：2666，阅读时长大约4分钟 作者 | 第一财经 周楠 连续三年虚增营收，其中两年的虚增金额占到当期总营收五成以上，控股股东正在推进破产重整的 ST立方（300344.SZ），因上述财务造假问题吃下大额罚单，并由此拉响退市"警钟"。 如今，ST立方在"戴帽"半年之后还将"披星"。根据安排，该股将于12月1日开市起停牌，次日复牌后 股票简称变更为*ST立方。公司同时提到， 若后续正式处罚出炉，公司被认定触及重大违法强制退 市情形，将被终止上市。 基本面上，ST立方已亏损累累，近五年扣非净利润累计亏损超10亿元。公司控股股东正在推进破产 重整，持股5%以上股东的部分持股近期则遭遇流拍。 连续三年财务造假 早前，ST立方4月底披露，公司因定期报告涉嫌信披违法违规被证监会立案。 ...

Core Viewpoint - R Puli 1 (Puli Pharmaceutical Co., Ltd.) is facing significant regulatory scrutiny and financial challenges, including a recent fine for failing to disclose its 2024 annual report on time, which adds to its existing issues related to previous financial misconduct [1][2][3]. Group 1: Regulatory Issues - On November 28, R Puli 1 received an administrative penalty notice from the Hainan Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for not disclosing its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan [1]. - The company had previously faced penalties for financial fraud, including a total of 1.029 billion yuan in inflated revenue and 669 million yuan in inflated profits over two years, leading to a fine of 10 million yuan and market bans for key executives [3]. Group 2: Financial Challenges - As of the end of Q3 2024, R Puli 1 reported cash reserves of only 331 million yuan, while its short-term liabilities due within a year amount to 541 million yuan, indicating a concerning short-term solvency issue [4]. - The company is under significant pressure from both the risk of delisting and a looming debt crisis, exacerbated by the recent regulatory penalties [4].

Core Viewpoint - ST Lifan is facing severe financial fraud allegations, which may lead to its delisting from the stock market due to continuous financial misconduct from 2021 to 2023 [2][5][10]. Financial Misconduct - From 2021 to 2023, ST Lifan inflated its revenue by a total of 638 million yuan and costs by 628 million yuan through various fraudulent activities [10]. - The breakdown of inflated figures includes: - 2021: Revenue inflated by 280 million yuan, costs inflated by 277 million yuan - 2022: Revenue inflated by 312 million yuan, costs inflated by 305 million yuan - 2023: Revenue inflated by 46 million yuan, costs inflated by 45 million yuan [10]. Regulatory Actions - The Anhui Securities Regulatory Bureau plans to impose a total fine of 40 million yuan on ST Lifan and related responsible individuals due to the financial fraud [5]. - ST Lifan has been warned and fined 10 million yuan, while 10 responsible individuals, including the chairman and general manager, face a combined fine of 30 million yuan and a 10-year market ban [10]. - The case involving the accounting firm associated with ST Lifan is under formal investigation for failing to fulfill its duties [10]. Delisting Risk - ST Lifan is at risk of being forcibly delisted due to serious violations of securities laws, with the Shenzhen Stock Exchange initiating delisting procedures [5][12]. - The company's stock will be suspended from trading starting December 1 and will be subject to delisting risk warnings upon resumption [12]. Financial Performance - ST Lifan has reported continuous losses over the years, with a recent financial summary indicating a total revenue of 2.03 billion yuan and a net loss of 620 million yuan for the latest reporting period [14]. - The company has seen a decline in its stock price, closing at 3.36 yuan per share, with a total market capitalization of 2.2 billion yuan as of November 28 [15]. Shareholder Information - As of October 20, ST Lifan had over 30,000 shareholders, with a slight decrease in the number of shareholders noted in recent periods [16][17].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Wuzhong*) has been forced to delist from the A-share market due to years of financial fraud, as confirmed by the China Securities Regulatory Commission (CSRC) [2][4][6] Financial Misconduct - *ST Wuzhong* failed to disclose the actual controller from 2018 to 2023, misrepresenting Qian Qunying as the actual controller instead of Qian Qunshan [4][6] - The company inflated revenue and profits significantly from 2020 to 2023, with a total inflated revenue of 1.771 billion yuan and inflated profits of 75.9975 million yuan over four years [5][6] - The company also failed to disclose non-operating fund occupation by related parties, with the amount occupied increasing from 127 million yuan in 2020 to 1.693 billion yuan in 2023, representing 96% of the disclosed net assets [5][6] Regulatory Actions - The CSRC imposed a maximum penalty on *ST Wuzhong*, including a fine of 10 million yuan and a 10-year market ban on actual controller Qian Qunshan [6] - The company’s stock will be suspended from trading starting November 26, 2025, pending a review by the Shanghai Stock Exchange regarding its delisting [6] Company Performance - *ST Wuzhong* reported revenues of 1.872 billion yuan in 2020, declining to 1.599 billion yuan in 2024, with net profits fluctuating from -506 million yuan to 70.48 million yuan during the same period [8] - In the first three quarters of 2025, the company experienced a 38.85% decline in revenue year-on-year, with a net loss of 87.47 million yuan, attributed to decreased income from pharmaceutical and medical beauty businesses [8] Medical Aesthetics Business - The company’s medical aesthetics segment, particularly the product AestheFill, was expected to turn around its financial performance, but faced challenges due to a dispute with a major competitor, Aimeike [9] - An arbitration case is ongoing regarding the exclusive distribution rights for AestheFill, which has hindered the company’s ability to sell the product [9]

Group 1 - The core issue revolves around ST Jinggu's proposed sale of a 51% stake in Huiyin Wood Industry to its controlling shareholder, Chow Tai Fook Investment, which has raised multiple inquiries from the Shanghai Stock Exchange regarding the major asset restructuring plan [1] - The company completed the acquisition of the 51% stake in Huiyin Wood in 2023, but the target company is expected to incur significant losses in 2024 and a substantial decline in performance in 2025 due to a civil litigation lawsuit leading to suspension of operations [1] - The Shanghai Stock Exchange has requested clarification on the prudence of the initial acquisition, the authenticity and completeness of the restructuring report and financial data, as well as the reasons for Huiyin Wood's performance decline and the rationality of performance forecasts and commitments [1] Group 2 - The inquiry also focuses on the repayment arrangements for fund borrowing, specifically the 13.26 million yuan principal and interest owed by Huiyin Wood, the expected scale on the delivery date, and the sources of funds for repayment [2] - The exchange has raised concerns regarding Huiyin Wood's involvement in a 313 million yuan civil loan lawsuit and the early maturity of 148 million yuan in bank loans, requesting explanations on the adequacy of expected liability provisions, risk isolation measures, and the status of bank creditors' consent [2] - Additionally, the company is required to disclose details regarding impairment-related receivables and to assess the accuracy of significant impairment provisions, considering the situation of asset freezes [2]

Core Viewpoint - The stock of ST Zhongdi experienced an abnormal price fluctuation with a cumulative increase of 18.07% over three consecutive trading days from November 18 to 20, 2025, despite poor financial performance and a change in control of the company [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 134.71 million yuan, a year-on-year decrease of 52.64% [1] - The total profit for the same period was -151.07 million yuan, reflecting a year-on-year decline of 41.83% [1] - The net profit after deducting non-recurring items was -132.35 million yuan, down 34.12% year-on-year [1] Change in Control - The controlling shareholder has changed to Shenzhen Tianwei Investment Partnership (Limited Partnership), with the actual controllers now being Men Hongda and Zhang Wei [1] Risk Warnings - The company has highlighted several risks including the divergence of stock price from fundamentals, poor performance, debt defaults, and legal issues related to guarantees, urging investors to make cautious decisions [1]

Core Viewpoint - The company is facing significant financial challenges, with a projected negative net profit for 2024 and a risk of delisting due to non-compliance with stock exchange regulations [2][7]. Group 1: Financial Performance - The audited net profit for 2024, excluding non-recurring gains and losses, is expected to be negative, with operating revenue below 300 million yuan after excluding unrelated business income [2][7]. - For the first three quarters of 2025, the company reported operating revenue of 109 million yuan and a net profit attributable to shareholders of -2.1294 million yuan, with a net profit of -2.5239 million yuan after excluding non-recurring gains and losses (unaudited) [2][7]. Group 2: Regulatory Compliance - The company is at risk of being flagged for delisting, with the stock set to receive a warning on April 29, 2025, due to the financial conditions outlined in the Shanghai Stock Exchange rules [2][7]. - If the company encounters any of the conditions specified in the stock exchange regulations in the second year of being flagged, it may face financial delisting [2][7]. Group 3: Share Transfer Activity - Hainan Bocheng Huineng Technology Center (Limited Partnership) is in the process of acquiring a total of 25.01% of shares from Zhejiang Hengshun Investment Co., Ltd. and Shanghai Tianji Investment Co., Ltd. through a transfer agreement, but the completion of this transaction remains uncertain [2][6]. Group 4: Market Risks - The company's stock experienced consecutive price increases on November 14 and 17, 2025, indicating significant short-term volatility, prompting a reminder for investors to be cautious [3][5]. - The company emphasizes the importance of understanding market risks and encourages rational investment decisions [5][8]. Group 5: Disclosure and Communication - The company assures that there are no undisclosed significant matters affecting stock price fluctuations and that all relevant information will be disclosed through designated media [4][10].